|
|
Post by awesomo on Nov 17, 2019 17:41:04 GMT -5
Great for them, but I don’t think you got that people are slowly and prematurely dying and that number is growing around the world. No sarcasm or economics or shorting or bashing is going to change that, except when they can start controlling their sugars effectively. I think you don’t understand that we invested in a company, not gave to a charity. And even if MannKind’s sole goal was to better the lives of diabetics, management has been a huge failure in that so far as well. |
|
|
|
Post by buyitonsale on Nov 17, 2019 19:11:24 GMT -5
I understand what I invested in and I am staying invested until I win.
And as I am waiting and keep on averaging down I also try to stay very positive.
Keeping my stream here and on ST as clean and as genuine as possible also helps.
This is what works for me.
|
|
|
|
Post by uvula on Nov 17, 2019 20:03:45 GMT -5
Will Cipla pay for Afrezza to be used in the upcoming trials in India? .... or does Mannkind provide A at no charge for the trials in India? When will Mannkind ship Afrezza to India for the trials? .... as soon as Dec or Jan? As i recall, India turned down cipla's request to sell A and is requiring a local clinical trial. Mnkd never said they would pay for it. Cipla never said they would pay for it either. The complete absence of comments from mnkd makes be think that India is a dead deal. I hope I'm wrong. I was hoping someone would say "You moron. You are spreading FUD. XXX has said that they are going to pay for the India trials and they will be starting on YYY and should be finished by ZZZ". But so far.....nothing. I hate being right. It doesn't happen often. Please point out that I am wrong. |
|
|
|
Post by mango on Nov 17, 2019 20:35:16 GMT -5
As i recall, India turned down cipla's request to sell A and is requiring a local clinical trial. Mnkd never said they would pay for it. Cipla never said they would pay for it either. The complete absence of comments from mnkd makes be think that India is a dead deal. I hope I'm wrong. I was hoping someone would say "You moron. You are spreading FUD. XXX has said that they are going to pay for the India trials and they will be starting on YYY and should be finished by ZZZ". But so far.....nothing. I hate being right. It doesn't happen often. Please point out that I am wrong. I think Mike talked some about the India clinical trial in the most recent call. I didn’t hear mention of anything that made me suspect it may not happen if MannKind has to solely fund. Have you emailed IR about it? |
|
|
|
Post by brotherm1 on Nov 17, 2019 20:57:52 GMT -5
I’ll email investor relations about the status of the India alleged clinical trials. I never once contacted MNKD before and would like to do so, though I could only find the phone number on the website for IR and not the email address. Does anyone here have it to share?
|
|
|
|
Post by goyocafe on Nov 17, 2019 21:02:41 GMT -5
I’ll email investor relations about the status of the India alleged clinical trials. I never once contacted MNKD before and would like to do so, though I could only find the phone number on the website for IR and not the email address. Does anyone here have it to share? IR@mannkindcorp.com |
|
|
|
Post by brotherm1 on Nov 17, 2019 21:13:19 GMT -5
Thank you. I just sent the email requesting current status of the Afrezza clinical trial in India and asked for it’s trial number. Will keep all here posted as soon as I hear back.
|
|
|
|
Post by mnholdem on Nov 18, 2019 13:27:47 GMT -5
Will Cipla pay for Afrezza to be used in the upcoming trials in India? .... or does Mannkind provide A at no charge for the trials in India? When will Mannkind ship Afrezza to India for the trials? .... as soon as Dec or Jan?
"MannKind will receive a $2.2 million upfront payment from Cipla within 30 days of entering the agreement, with the potential to receive additional regulatory milestone payments, minimum purchase commitment revenue and royalties on Afrezza sales in India."Source: investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-cipla-enter-exclusive-marketing-and-distribution |
|
|
|
Post by uvula on Nov 18, 2019 14:03:20 GMT -5
The press release doesn't answer the question. Approval is never guaranteed. Cipla paid the costs to submit afrezza for approval and it was denied. Now what? Nothing says that Cipla will now pay for an India clinical trial. All we know is that mnkd never agreed to pay for it.
Cipla tried and failed to get approval. Cipla might be out the money they paid to mnkd but they are not required to do anything else.
Is afrezza in india another failed initiative? We don't know. It will be iteresting if IR replies to the email.
|
|
|
|
Post by mnholdem on Nov 18, 2019 14:36:11 GMT -5
That’s not what I remember. Cipla applied for an accelerated pathway and was denied. So they simply have to take the normal pathway for approval.
|
|
|
|
Post by mnholdem on Nov 18, 2019 14:37:39 GMT -5
India will sometimes grant approval based upon FDA data alone.
|
|
|
|
Post by uvula on Nov 18, 2019 15:52:20 GMT -5
|
|
|
|
Post by spikespiegel on Nov 18, 2019 16:06:18 GMT -5
Mannkind mentioned it in the Q3 Call under "Near Term Key Milestones
-initiate Phe 3 Clinical Study in India ( India SEC has approved protocol)
see slide 22
|
|
|
|
Post by hellodolly on Nov 18, 2019 18:15:17 GMT -5
Mannkind mentioned it in the Q3 Call under "Near Term Key Milestones -initiate Phe 3 Clinical Study in India ( India SEC has approved protocol) see slide 22 You FUD killer! |
|
|
|
Post by brotherm1 on Nov 18, 2019 21:46:29 GMT -5
Thank you. I just sent the email requesting current status of the Afrezza clinical trial in India and asked for it’s trial number. Will keep all here posted as soon as I hear back. FWIW, reply dated today: “Our partner in India is still in the planning stages for the registration trial that they will be conducting. Once the trial gets underway (expected in the New Year), we will provide an update.” |
|
